Core Viewpoint - Genflow Biosciences PLC is considering a potential equity raise through the issuance of new shares to fund its gene therapy programs aimed at age-related diseases [1] Group 1: Potential Equity Raise - The Board is seeking shareholder approval for the allotment of up to 188,947,368 new ordinary shares, which represents approximately 38% of the current issued share capital [1] - The equity raise may involve rights over new shares in the form of shares or warrants to new investors and/or existing shareholders on a non-pre-emptive basis [1] - The General Meeting to discuss this potential equity raise is scheduled for March 2, 2026, in London [1] Group 2: Use of Proceeds - Funds raised from the potential equity raise would be allocated to several key areas, including advancing the MASH program to the IND-enabling stage, completing payments for a clinical trial in aged beagle dogs, conducting glaucoma proof of concept studies, and finalizing EU patent approvals [1] Group 3: Company Overview - Genflow Biosciences, founded in 2020, focuses on developing gene therapies for age-related diseases, with a lead compound, GF-1002, showing promising preclinical results [1] - The company aims to address the challenges posed by an aging global population by promoting longer and healthier lives [1]